{
    "pmcid": "7685322",
    "qa_pairs": {
        "How was the lead nanobody Nanosota-1C further engineered to improve its pharmacokinetic properties?": [
            "By adding an Fc tag to create a bivalent construct, Nanosota-1C-Fc",
            "By increasing its size through polymer conjugation",
            "By fusing it with a human antibody fragment",
            "By incorporating a polyethylene glycol (PEG) moiety"
        ],
        "In what model did Nanosota-1C-Fc demonstrate both preventive and therapeutic efficacy against SARS-CoV-2 infection?": [
            "Hamster model",
            "Mouse model",
            "Ferret model",
            "Non-human primate model"
        ],
        "What is the dissociation constant (Kd) of Nanosota-1C-Fc for the SARS-CoV-2 RBD?": [
            "15.7 picomolar",
            "1.5 nanomolar",
            "157 micromolar",
            "0.15 millimolar"
        ],
        "What is the molecular weight range of nanobodies as described in the summary?": [
            "12\u201315 kDa",
            "50\u201360 kDa",
            "25\u201330 kDa",
            "100\u2013150 kDa"
        ],
        "What is the production yield of Nanosota-1C-Fc in bacterial systems without optimization?": [
            "40 mg/L",
            "10 mg/L",
            "100 mg/L",
            "5 mg/L"
        ]
    }
}